CorMedix (NYSE: CRMD) reported Q2 EPS of ($0.13), $0.02 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $16.51 million, versus $119.97 million reported last year.

For earnings history and earnings-related data on CorMedix (CRMD) click here.